For listeners who wish to participate in the question and answer session via telephone, please pre-register here. All registrants will receive dial-in information and a PIN allowing them to access the live call. In addition, a live audio of the conference call will be available as a webcast. Interested parties can access the event through the "Events" page on the Pacira website at investor.pacira.com. For those unable to participate in the live call, a replay of the webcast will be available on the Pacira w ...

Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors use tried-and-true metrics and fundamental analysis to find companies that they believe are undervalued at their current share price levels. One stock to keep an eye on is Pacira BioSciences (PCRX) . PCRX is currently sporting a Zacks Rank of #2 (Buy) and an A for Value. Value investors also love the P/S ratio, which is calculated by simply dividing a stock's price with the compan ...

The proposed rule is part of the implementation of the Non-Opioids Prevent Addiction in the Nation Act, which requires separate CMS payments for qualifying non-opioid drugs and devices in HOPD and ASC settings. This law was included in the Consolidated Appropriations Act of 2023. To date, Exparel has been used in more than 14 million patients across the United States. The proposed Medicare payment rates for covered non-opioid drug products, as outlined in the rule, will be set at the average sales price plu ...

-- Proposed Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment System Rule extends separate payment from ambulatory surgical centers to include the hospital outpatient environment – "Following several years of advocacy for reimbursement policy reform to allow increased patient and provider access to non-opioids, we are pleased to see EXPAREL included as one of only six qualifying non-opioid drugs to treat postsurgical pain in the proposed rule," said Frank D. Lee, Chief Executive ...

The proposed rule reflects impending implementation of the Non-Opioids Prevent Addiction in the Nation (NOPAIN) Act, which mandates separate CMS payment for qualifying non-opioid drugs and devices across HOPD and ASC settings. The law was passed as part of the Consolidated Appropriations Act of 2023. | --- | --- | |----------------------------------|---------------------------------------------------------| | | | | Non-Opioid Drug | Proposed Separate CMS Payment Rate (Per Billing Unit)* | | EXPAREL | $1.41 ...

It has been about a month since the last earnings report for Pacira (PCRX) . Shares have added about 1.7% in that time frame, underperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Pacira due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Pacira Q1 Earnings Miss, Exparel Sales Drive Revenues ...

1Q24 Earnings Presentation May 2024 Forward-looking statements and where to find additional information This presentation contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the Private Securities Litigation Reform Act of 1995, including, without limitation, statements related to: our growth and future operating results and trends, our strategy, plans, objectives, expectations (financial or otherwise) and intentio ...

Pacira BioSciences, Inc. (NASDAQ:PCRX) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Susan Mesco - Head of Investor Relations Frank Lee - Chief Executive Officer Charles Reinhart - Chief Financial Officer Jonathan Slonin - Chief Medical Officer Christian Pedetti - Senior Manager, Investor Relations Conference Call Participants Gregory Renza - RBC Capital Markets David Amsellem - Piper Sandler Gary Nachman - Raymond James Balaji Prasad - Barclays Operator Thank you for standing ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35060 PACIRA BIOSCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) (State or Other Jurisdiction of Incorpora ...

FOR IMMEDIATE RELEASE See "Non-GAAP Financial Information" below. "Sales are off to a solid start for all three of our trusted, opioid-sparing products and we remain sharply focused on driving accelerated growth in 2025 and beyond," said Frank D. Lee, chief executive officer of Pacira BioSciences. "We are pleased with the progress we are making advancing the launch of EXPAREL in two new lower extremity nerve block indications, and we are receiving positive market receptivity across all sites of care. We are ...